presentation: gmp clearance · • mra pathway not available for manufacturing sites in usa • us...
TRANSCRIPT
GMP Clearance
Stephen Farrell Director (A/g), GMP Clearance SectionDarika Sowana Assistant Director, GMP Clearance Section
Overview• Where we are now, future direction and focus• GMP agreements and the PIC/S guide• Answers to Industry’s most frequently asked questions• GMP Clearance for listed, over-the-counter and prescription medicines
1
Where we are now, future direction and focus
2
Background - January 2016• GMP Clearance team of 7 within the
licensing and certification section:– 4 in application receipt– 3 in assessment
• Mutual Recognition Agreement (MRA) backlog
• Compliance Verification (CV) backlog
3
Background - January 2016• Sterile CV’s performed by Inspectors• GMP Clearance mailbox backlog• Extensions backlog• Transfers and name changes backlog• Outdated guidance• Poor system processing and data capture• Poor quality applications
4
Progress – 2016 to 2017
Initially Targeted
MRA, extension and email backlogs
Improved internal
monitoring and
reporting capabilities
Re-designed the
application e-form
Re-wrote the GMP
Clearance guidance and
introduced CAAT
Streamlined receipt and assessment processes
Recruitment
Training
Measure
5
Progress – 2018 to 2019
Reduction of the CV back-
log
Introduced TGA vs
industry time
Several guidance updates
Published new target timeframes
Recruitment
Training
Measure
6
November 2019• We are now a GMP Clearance Section of
20 staff ‒ 5 in application receipt‒ 15 in assessment
• No backlogs across the section• Accurately capturing TGA vs Industry time• Improved data analytics to ensure no
return to backlog7
November 2019• Published processing times‒ MRA – 30 working days‒ Non Sterile API – 60 working days‒ Sterile API – 75 working days‒ Non Sterile finished product – 90 working days‒ Sterile finished product – 120 working days
8
Our impact
7%
93%
Overseas Manufacturers
On-site Inspections
GMP Clearance
68%
32%
MRA vs CV
MRA
CV
44%56%
API vs Product
API
Product
9
MRA or equivalent breakdown
3.30%
92.03%
3.71%
0.96%
0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00% 90.00% 100.00%
CANADA
EUROPE
NEW ZEALAND
SINGAPORE
MRA Pathway
10
Compliance verification breakdown
44.79% 27.41% 9.94% 4.36%
1.89%
1.76%
1
CV pathway
India US China Japan Israel
Taiwan Korea - Republic of Mexico Slovenia Argentina
Romania Turkey Croatia Bulgaria Macau - SAR of China
Thailand Brazil United Arab Emirates United Kingdom Malaysia
Oman South Africa Serbia - Republic of Bangladesh Chile
Hong Kong - SAR of China Indonesia Italy Jordan Canada
11
GMP clearance metrics
649 606 584 572 548 559 530 561 525 494 504 494 512 520 518 487 482 492 452 432
85136 172 169 166
221182 156 159
196 209170 168 176
139 146189 161 152
106
0
100
200
300
400
500
600
700CVs total MRAs total
12
CV applications by type
13
CV incoming vs outgoing
14
CV applications (474) - status breakdown
1 Nov 201915
MRAs not issued
16
CVs not issued
17
Future direction and focus• Expect a period of stability • Continue to select complete over incomplete applications• Further education and engagement with industry• Focus will be on internal processes and improvements• Continue to evolve our data analytic capabilities • Only action true priority requests i.e. for reported medicine
shortages• Increased involvement in the Indo-Pacific Regulatory
Strengthening Program
18
Future direction and focus• Increased focus on 2 key areas of
assessment:– Release For Supply– GMP agreements
• These areas are the biggest source of deficiencies for finished product GMP Clearances
19
Future direction and focusWhy focus on Release for Supply and GMP agreements?
– Australia has no Qualified Person (QP) system – We do not license our sponsors or regulate Good
Distribution Practice (GDP)– Proposed update to Annex 16 (Certification by the
Authorised Person and Batch Release)
20
21
GMP agreements and the PIC/S guide
22
Manufacturer outsourced activities• Cleaning• Training• Waste management• Outsourced engineering for
facilities and equipment• Contract hire services• Suppliers of materials and
components
• Regulatory affairs consultants• Outsourced vendor auditing• Expert consultation• Certification• Calibration• Testing and analysis• Contract manufacture
23
MAH Outsourced
Activities
Finished Product
MNF
Testing Laboratory
Alternative Finished Product
MNF
Alternative Testing
Laboratory
MAH Outsourced
Activities
Finished Product
MNF
Testing Laboratory
Alternative Finished Product
MNF
SteriliserSecondary packaging
MNF
API/Drug Substance
MNF
Release for Supply (AP)
OR
24
PIC/S Chapter 7
Clause (updated text in red) Requirements for GMP Clearance
7.1 There should be a written contract covering the outsourced activities, the products or operations to which they are related, and any technical arrangements made in connection with it.
All outsourced activities need to be covered by a contract
7.3 Where the Marketing Authorisation holder and the manufacturer are not the same, appropriate arrangements should be in place, taking into account the principles described in this chapter.
Generally, contracts must be in place between the sponsor and manufacturer
25
PIC/S Chapter 7Clause (updated text in red) Requirements for GMP Clearance
The Contract Giver7.4 The Pharmaceutical Quality System of the Contract Giver should include the control and review of any outsourced activities. The Contract Giver is ultimately responsible to ensure processes are in place to assure the control of outsourced activities. These processes should incorporate quality risk management principles….
How is the Contract Acceptor reviewed/controlled?
MAH should demonstrate the suitability/legality of the contract acceptor.
7.4.1 Prior to outsourcing activities, the Contract Giver is responsible for assessing the legality, suitability and the competence of the Contract Acceptor to carry out successfully the outsourced activities. The Contract Giver is also responsible for ensuring by means of the contract that the principles and guidelines of GMP as interpreted in this Guide are followed.
26
PIC/S Chapter 7
Clause (updated text in red) Requirements for GMP Clearance
7.4.3 The Contract Giver should monitor and review the performance of the Contract Acceptor and the identification and implementation of any needed improvement.
Need processes for monitoring of outsourced activity
27
PIC/S Chapter 7Clause (updated text in red) Requirements for GMP Clearance
7.7 The Contract Acceptor should ensure that all products, materials and knowledge delivered are suitable for their intended purpose.
Evidence of appropriate knowledge transfer
7.8 The Contract Acceptor should not subcontract to a third party any of the work entrusted under the contract without the Contract Giver’s prior evaluation and approval of the arrangements. Arrangements made between the Contract Acceptor and any third party should ensure that information and knowledge, including those from assessments of the suitability of the third party, are made available in the same way as between the original Contract Giver and Contract Acceptor.
Evidence of appropriate knowledge transfer
MAH must be made aware of subcontracting as well as issues with subcontractors
28
PIC/S Chapter 7Clause (updated text in red) Requirements for GMP Clearance
7.11 A contract should be drawn up between the Contract Giver and the Contract Acceptor which specifies their respective responsibilities and communication processes relating to the outsourced activities. Technical aspects of the contract should be drawn up by competent persons suitably knowledgeable in related outsourced activities and Good Manufacturing Practice. All arrangements for outsourced activities must be in accordance with regulations in force and the Marketing Authorisation for the product concerned and agreed by both parties.
Modification to existing agreements may be required
Review and assess the suitability of your existing agreements
Emphasis may need to be on the communication processes to ensure these are clear and unambiguous
29
PIC/S Chapter 7Clause (updated text in red) Requirements for GMP
Clearance
7.12 The contract should describe clearly who undertakes each step of the outsourced activity, e.g. knowledge management, technology transfer, supply chain, subcontracting, quality and purchasing of materials, testing and releasing materials, undertaking production and quality controls (including in-process controls, sampling and analysis).
Some modification to existing agreements required
MAH access to documents required
Supply chain integrity
7.13 All records related to the outsourced activities, e.g. manufacturing, analytical and distribution records, and reference samples, should be kept by, or be available to, the Contract Giver. Any records relevant to assessing the quality of a product in the event of complaints or a suspected defect orto investigating in the case of a suspected falsified product must be accessible and specified in the relevant procedures of the Contract Giver.
30
Chapter 1 pharmaceutical quality systemProduct Quality Reviews (PQR) Requirements for GMP Clearance
1.11 The manufacturer and, where different, Marketing Authorisation holder should evaluate the results of the review and an assessment made as to whether corrective and preventive action or any revalidation should be undertaken, under the Pharmaceutical Quality System. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures verified during self-inspection. Quality reviews may be grouped by product type, e.g. solid dosage forms, liquid dosage forms, sterile products, etc. where scientifically justified.
MAH to review the annualPQR and ensure a mechanism is in place for any potential required actions
One of these reviews is regarding Market Authorisation variations (1.10 vi) submitted, granted or refused
31
Chapter 1 pharmaceutical quality systemPQR Continued Requirements for GMP Clearance
Where the Marketing Authorisation holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the product quality review. The Authorised Person responsible for final batch certification together with the Marketing Authorisation holder should ensure that the quality review is performed in a timely manner and is accurate.
Contracts should cover the MAH input into and subsequent review of the PQR
32
33
Industry’s most frequently asked questions
34
Communication and educational materials• Since January 2019, we have implemented
a range of communication, educational materials and activities to provide support for industry
• Continuing efforts to seek feedback to inform our stakeholder engagement and regulatory activities
35
GMP Clearance Guidance
V 18.3
Clearance ApplicationAssistance Tool (CAAT)
GMP Application
Decision Tree
Educational Materials and
Communications
News UpdateWebinars
GMP Clearance Application
36
General feedback mechanisms• TGA Industry Working Group on GMP
(TIWGG) industry association members• GMP Clearance Inbox• Additional Research Initiative - GMP
Clearance Industry Survey (Aug-Sep 2019)
37
GMP clearance industry survey• 196 completed the survey in full• 62.4 % - mostly satisfied with the current
communication• 96% refer to GMP Clearance guidance
when submitting application• 58% - aware of the Clearance Application
Assistance Tool (CAAT)
38
General GMP clearance process
39
I want to import a dietary supplement from the US, what information do I need to provide and can I access the MRA pathway?
• MRA Pathway not available for manufacturing sites in USA• US FDA does not regulate dietary supplements the same way as Australia• US FDA applies dietary supplement GMP standards which is not the same as the US FDA drug
GMP standard • For a dietary supplement manufacturer in USA, it is most likely that a TGA on-site inspection will be
required
40
How does TGA determine the period of GMP clearance validity? What is the maximum expiry the TGA provides?
• The validity is typically 3 years plus 6 months• The 6 months additional validity is essentially an automatic extension• In some cases, validity may be reduced because:
– condition placed by the regulator – compliance issues– determined during an assessment of the evidence
41
If TGA has conducted an on-site audit, does TGA issue a GMP clearance to the sponsor or does the sponsor have to apply for a GMP clearance post TGA inspection?• TGA overseas on-site inspection = TGA Certification (CE) application• GMP Clearance issued after the inspection is successfully closed out.• GMP Clearance automatically issued to sponsors who contribute towards the
inspection cost
42
If my application is marked to ‘with manufacturer’ what does this mean? Shouldn’t I have received a ‘request for information’?
• The status ‘With Manufacturer’ indicates a stop clock is applied• Reasons:
‒ Outstanding fee payment‒ Missing or incorrect evidence i.e. incomplete application‒ Deficiencies identified during assessment
43
I am experiencing issues in validating my clearance for a product listing / variation? The validation message says my clearance is not licensed for the selected dosage form, what should I do?• Confirm the relevant regulatory area - dosage form and/or manufacturing steps for your
listing application. • Then submit either a clearance application or a variation to include correct scope
44
GMP clearance extension
45
My clearance has expired for 6 months. Unfortunately my predecessor did not apply for extension at the time prior to their departure from the organisation. Can I please get an extension on the clearance?• Extension requests can be submitted up to 30 days after the expiry date
of their GMP clearance• Expired GMP clearances (i.e. > 30 days) may be reinstated at your
request • The fee to reinstate a GMP Clearance is $1,180
46
How to deal with timing issues when GMP clearance is due to expire and a competent authority has not yet inspected the site, or has inspected the site but the report/certificate is not yet available?
• MRA - submit an extension request (TBS portal) - stating the reason
• CV - if no acceptable evidence, then the alternative option is a TGA on-site inspection
47
What is the impact of Brexit on my GMP Clearances?• Due to Brexit, the MHRA has recently issued a number of
GMP Certificates from a desktop assessment (DTA) for UK manufacturing sites
• MHRA DTA GMP Certificate is accepted for extension requests
• MHRA DTA GMP Certificate is not sufficient evidence for a full renewal of a clearance
48
GMP clearance evidence
49
Besides poor quality documents what other common reasons are GMP clearances not issued?
• Inequivalent GMP standards used• Inadequate or no responses received as requested during assessment• Insufficient detail in the inspection reports • Expired evidence • Lack of clarity in GMP Agreements and supply chains
50
51
GMP Clearance for Complementary, Over-the-counter and Prescription Medicines
52
Product registration or listing on the ARTG• GMP Clearance is not just a pre-requisite to register or list a
medicine. Maintaining the on-going validity is required• Product regulators determine what steps of manufacture get
recorded• Increasing use of automated lodgement systems which have pre-
set validation rules• GMP is applicable to all medicines therefore the selectable
dosage forms or manufacturing steps is extensive• Refer to existing product relevant guidance to avoid having to
submit variations to correct errors
53
Complementary medicines• GMP Clearance is required prior to submitting your listing application • Generally not required to be provided for Active Pharmaceutical Ingredients• There are 6 manufacturing steps generally applicable for complementary medicines:
– Manufacture of dosage form– Packaging and labelling– Secondary packaging– Testing chemical and physical– Testing microbial– Release for Supply
54
Complementary medicines• Use the listed and assessed listed guidance
when submitting GMP Clearance applications• Contains a list of the correct dosage forms that
will validate • https://www.tga.gov.au/sites/default/files/listed-
assessed-listed-medicines-application-submission-user-guide.pdf
55
Over-the-counter medicines• GMP Clearance is required prior to submitting your registration application • It is generally not required to be provided for APIs however its required for
intermediate product (e.g. API mix or premix)• There are 8 manufacturing steps generally applicable for OTC medicines:
‒ API active premix (where applicable)‒ Manufacture of Dosage form‒ Packaging and Labelling‒ Secondary packaging‒ Testing chemical and physical ‒ Testing microbial ‒ Release for Supply‒ Sterilisation (Where applicable) 56
Prescription medicines• The requirements for GMP Clearance can differ depending on
whether the prescription medicines is:‒ Chemically derived‒ Biological medicine
• Generally, GMP Clearance is required for both API/drug substance manufacture and Finished product manufacture
• We are finalising an update to the ‘Evidence of GMP Compliance for Prescription Medicines’ guidance
57
Prescription medicines – API/drug substance• Chemically derived:
‒ Active Material Manufacture including manufacture of the crude, synthesis and purification of the API
• Biological Medicines:‒ Working cell bank (WCB) manufacture, storage and
maintenance‒ Active Material Manufacture‒ Any test performed on the drug substance used for
Release for Supply that is not repeated on the finished product
58
Prescription medicines – finished product• Manufacture of dosage form (including manufacture of intermediates)• Manufacture of diluent• Primary Packaging and labelling• Secondary packaging (including assembly of kits and composite packs)• Sterilisation• Chemical and Physical Testing• Microbiological Testing (including endotoxin and sterility)• Biological Testing• Release for Supply
59
Visit the GMP clearance tableDrop by and have a chat with Rheannon, Jodie and Karman from the GMP Clearance section who can provide guidance on:• Any questions you have about GMP Clearance in general• Any questions you have about your specific GMP Clearance
application
Don’t forget to grab a copy of our handy GMP Clearance QR code reference page for easy access to all our guidance and information!
60
61